Azevan Pharmaceuticals, Inc., is a clinical stage, small molecule drug development company developing novel therapeutics to treat disorders of stress, mood, and behavior. The company’s first clinical compounds selectively block the effects of arginine vasopressin, a peptide neurohormone involved in the pathophysiology of major depression, intermittent explosive disorder, impulse control/anger disorders, and post-traumatic stress disorder (PTSD). Vasopressin receptor antagonists represent a novel mechanism of action for addressing these indications.
CEO and Chairman
Neal G. Simon, Ph.D.